Anti-vascular endothelial growth factor (anti-VEGF) and laser combination therapy demonstrates variable efficacy in severe non-proliferative diabetic retinopathy, with 30–45% of patients experiencing suboptimal outcomes. This evidence concerns the gene VEGFA and non-proliferative diabetic retinopathy.